Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for April 10, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at [http://www.cdc.gov/nmi/faq.html](http://www.cdc.gov/nmi/faq.html). If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

**Message Mapping Guide Development Updates**

- The Message Mapping Guide (MMG) Development Team determined the conditions included in the Generic v2 MMG.
  - Most jurisdictions will be able to use the Generic v2 MMG for 54 conditions.
  - National Electronic Disease Surveillance System Base System (NBS) jurisdictions will be able to use it for 52 conditions.
- The team expects to post several resource documents on the [Draft MMG Web site](http://www.cdc.gov/nmi/faq.html) when they are finalized and cleared, including a summary of case notification messaging updates to reflect the restructuring of the latest MMGs and the updated PHIN Messaging Guide for Case Notifications Release 3.0.
- **Message Mapping Guide (MMG) Status Updates:**
  - **Mumps and Pertussis MMGs (Stage I—Draft Phase):**
    - The MMG Development Team has revised the expected posting date for the revised Mumps and Pertussis MMGs to April 2015 for a second external review period of approximately 3 weeks.
  - **Congenital Syphilis and STD MMGs (Stage III—Reconciled Draft Phase):**
    - The team revised the STD MMG in response to changes suggested by the NBS Team and the Message Validation, Processing, and Provisioning System (MVPS) developer AgileX and delivered an updated MMG, test scenarios, and test messages to the MVPS Team in March 2015.
The MMG Development Team revised the Congenital Syphilis MMG in response to changes suggested by the NBS Team and AgileX and delivered an updated MMG, test scenarios, and test messages to the MVPS Team on 4/3/2015.

The MMG Development Team will post the STD and Congenital Syphilis MMGs as soon as possible as **Stage III—Pilot Test-ready Draft Phase** versions of the MMGs, along with their artifacts.

- **Generic v2 and Hepatitis MMGs** (**Stage III—Pilot Test-ready Draft Phase**)
  - The team revised the Generic v2 and Hepatitis MMGs in response to changes suggested by the NBS Team and AgileX and delivered updated MMGs, test scenarios, and test messages to the MVPS Team in March 2015.
  - The MMG Development Team expects to post updated versions of the Generic v2 and Hepatitis artifacts to the Draft MMG Web site in April 2015.

- No guides are in **Stage IV—Final MMG Phase** at this time.

**Message Validation, Processing, and Provisioning System Updates**

- The MVPS Team delivered the updated message processing guides (MPGs) and processing requirements documents to AgileX for the restructured Generic v2, Hepatitis, and STD MMGs on 4/3/2015, as planned.
  - The team held final message processing clarification sessions with AgileX for Generic v2, STD, and Hepatitis on 4/8/2015.
- The team expects to complete the Congenital Syphilis MPG and processing requirements documents and provide them to AgileX in April 2015.
- The MVPS QC Dashboard role-based security functionality is expected to be delivered by AgileX to CDC in mid-April 2015. Internal CDC technical validation testing will begin shortly thereafter.
- The updated Message Evaluation and Testing Service (METS) tool is expected to be available in early June 2015 to support jurisdiction independent testing of their Hepatitis, STD, and Generic v2 messages. The MVPS QC Dashboard tool and message processing functionality is also expected to be available in June 2015 to support independent testing of Generic v2, Hepatitis, and STD messages by the jurisdictions and programs.
- The MVPS Team is working on creating the data provisioning requirements and data dictionary mapping for Generic v2, Hepatitis, and STD. They will be working with the CDC Surveillance Operations Team (SOT) and Message and Vocabulary Team as well as the CDC programs to review and validate the requirements prior to expected delivery to AgileX on 4/17/2015.

**Technical Assistance Updates**

- CDC posted the funding opportunity announcement (FOA) for the sole-source cooperative agreement that will fund APHL for NMI technical assistance (TA) activities starting in July 2015.
- For Generic v2, Hepatitis, and STD, APHL has received the MMGs and artifacts needed to begin TA work with the initial pilot jurisdictions.
- Once the MMG and artifacts are available for Congenital Syphilis, the APHL TA team will share the documents with pilot sites for orientation.
- The APHL TA team drafted the NMI technical assistance guidebook and shared it with the NMI Communication Workgroup for review on 4/6/15.
- Reminder about MMG status:
  - MMGs in Stages I, II, and III are considered draft and may be revised until the time they are finalized.
Those jurisdictions selected for pilot testing of the test-ready versions (Stage III) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.

All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage IV) have been posted to the PHIN website.

For more information about technical assistance:
- Please see the NMI FAQs at http://www.cdc.gov/nmi/faq.html.
- For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at laura.carlton@aphl.org.
- For non-pilot jurisdictions: If you have questions or would like to request TA for MMG implementation through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at http://www.cdc.gov/nmi/faq.html. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.